Leuprorelin acetate

醋酸亮丙瑞林

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLeuprorelin acetate
Drug Alias Name亮丙瑞林醋酸盐Leuprorelinum醋酸亮丙瑞林Leuprolide acetateleuprorelina +[26] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGonadotropin-releasing hormone agonists
TargetsGonadotropin-releasing hormone
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsPedophiliaParaphilic Disorders +[25] 
Global Approved IndicationsEndometriosisProstatic NeoplasmsUterine Neoplasms +[4] 
Approved Indications in ChinaEndometriosisProstatic NeoplasmsUterine Neoplasms +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1985/04/09
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMedivation LlcUniversity Medical Center GroningenWeill Medical College of Cornell University +[13] 
Inactive CompaniesAbbott LaboratoriesCanadian Institutes Of Health Research (Cihr)Institut National De La Santé Et De La Recherche Médicale, France U979 +[24] 
Active IndicationsHormone-Sensitive Prostate NeoplasmsCognitive DysfunctionPuberty, Precocious +[9] 
Inactive IndicationsPedophiliaParaphilic DisordersPremenstrual Syndrome +[16] 

Other Information

ATC CodeL02AE02
Related LinksWikipediaDrugBankKEGG